Aditxt Announces Pricing of $20.0 Million Public Offering

Rhea-AI Summary

Aditxt, Inc. (Nasdaq: ADTX) announced a public offering of 3,333,333 shares of common stock and associated warrants at $6.00 per unit, aiming to raise approximately $20 million. The warrants, with an exercise price of $6.00, are exercisable immediately and expire in five years. Proceeds will fund general corporate expenses, including R&D and potential acquisitions, although no current commitments are in place. Closing of the offering is expected around September 20, 2022, pending customary conditions. H.C. Wainwright & Co. is the exclusive placement agent.

Positive

• Intended to raise approximately $20 million for general corporate purposes, supporting R&D and potential expansions.
• Offers liquidity through warrants exercisable immediately, providing investors with options.

Negative

• Dilution risk exists due to the issuance of new shares and warrants, potentially affecting existing shareholders' value.

RICHMOND, Va.--(BUSINESS WIRE)-- Aditxt, Inc., (Nasdaq: ADTX) (the “Company” or “Aditxt”), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, today announced the pricing of a public offering of 3,333,333 shares of its common stock (or common stock equivalents in lieu thereof), together with warrants to purchase up to 3,333,333 shares of its common stock at a combined offering price to the public of $6.00 per share (or common stock equivalent) and associated warrants. The warrants will have an exercise price of $6.00 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about September 20, 2022, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds to the Company from the offering are expected to be approximately $20.0 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for general corporate purposes, which may include research and development expenses, capital expenditures, working capital and general and administrative expenses, and potential acquisitions of or investments in businesses, products and technologies that complement our business, although the Company has no present commitments or agreements to make any such acquisitions or investments.

The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-266183) initially filed with the Securities and Exchange Commission (SEC) on July 18, 2022 and became effective on September 16, 2022. The public offering is being made only by means of a prospectus, which forms a part of the effective registration statement. When available, electronic copies of the final prospectus may be obtained for free on the SEC’s website located at http://www.sec.gov and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Aditxt

Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune modulating technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies. For more information, please visit www.Aditxt.com and www.AditxtScore.com.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of federal securities laws. Forward-looking statements in this press release include, without limitation, the ability of the Company to close the offering and the use of proceeds therefrom. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product and business development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220916005105/en/

Media and Investor Relations Contact:

ir@aditxt.com

www.aditxt.com

Source: Aditxt

FAQ

What are the details of Aditxt's public offering?

Aditxt is offering 3,333,333 shares of common stock and warrants at $6.00 per unit, aiming to raise approximately $20 million.

What will Aditxt do with the proceeds from the offering?

The proceeds will be used for general corporate purposes, including R&D, capital expenditures, and potential acquisitions.

When is the closing date for Aditxt's public offering?

The closing of the offering is expected around September 20, 2022, subject to customary closing conditions.

Who is the placement agent for Aditxt's offering?

H.C. Wainwright & Co. is acting as the exclusive placement agent for Aditxt's public offering.

What are the risks associated with Aditxt's public offering?

The public offering may lead to dilution for existing shareholders due to the issuance of new shares and warrants.